Cross-validation of a Predictive Model of Response to Anti-TNF Alpha Based on Oxylipin Response in Rheumatoid Arthritis

The goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-TNF alpha treatment . The main questions it aims to answer is: Is the predictive model created using oxylipins effective? Participants starting anti-TNF alpha treatment will have a blood sample taken before starting treatment and 6 months afterwards.

NCT Number	NCT06880146
Lead Sponsor	University Hospital, Clermont-Ferrand Collaborators: Unité de Nutrition Humaine, INRAE, Centre Auvergne-Rhône Alpes, Immunology department, CHU Clermont-Ferrand, University of Southampton
Conditions	Rheumatoid Arthritis
Enrollment	30 participants
Start Date	2025-03-15
Primary Completion	2026-11-01 (estimated)
Study Completion	2027-11-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-17